Last reviewed · How we verify
MP-470
At a glance
| Generic name | MP-470 |
|---|---|
| Also known as | amuvatinib |
| Sponsor | Astex Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors (PHASE1)
- A Phase 2, Open-Label Study of Amuvatinib in Combination With Platinum-Etoposide Chemotherapy in Small Cell Lung Cancer (PHASE2)
- Safety Study to Determine the Maximum Tolerated Dose, Pharmacokinetics and Pharmacodynamics of Oral MP470, a Multitargeted Tyrosine Kinase Inhibitor, in Patients With Solid Malignancies (PHASE1)
- MP470 in Treating Patients With Unresectable or Metastatic Solid Tumor or Lymphoma (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- MP-470 CI brief — competitive landscape report
- MP-470 updates RSS · CI watch RSS
- Astex Pharmaceuticals, Inc. portfolio CI